KURA (29) AKTS (56) ORIC (39) CYRX (38) ⌘ Pro Terminal →

Rigel Pharmaceuticals Inc. (RIGL) — RQD Stock Rating Cockpit

$51.45 +1.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Rigel Pharmaceuticals Inc. (RIGL) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (93% profit margin, 28% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $961.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RIGL)Realized 20D OHLCV Swing Band: ±7.8%

RSI-14 MOMENTUMBULLISH MOMENTUM

64.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.64>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE96% OF RANGE

L: $25$51.45H: $53

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (93% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 29 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 32 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on RIGL

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

28.2% ROIC with 93.3% gross margin and 7.87% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 3.64 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (78)

29/40 institutional & smart-money positioning score with 18/20 macro alignment.

Bull Case: Why Buyers Like RIGL

✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RIGL Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RIGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +78.03%▲ ASCENDING CHANNEL

2026-10-30O $51.80H $52.61L $50.67C $51.45VOL 174.2K

RES: $55.96SUP: $47.94SMA50: $47.69SMA200: $37.15

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RIGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RIGL Butterfly Map → + Track RIGL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-3.0%/yr Implied 5Y Growth

vs. +64.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RIGL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RIGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RIGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RIGL)

Health Care Rank #56 of 1016 ⚔️ KURA vs RIGL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RIGL vs. KURA, AKTS, ORIC, CYRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rigel Pharmaceuticals Inc. (RIGL) ranks #56 by composite RQD confidence (74/100, grade B) and #363 by equity capitalization ($961.1M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while RIGL leads on capital efficiency and profitability with 28.2% ROIC and 93.3% gross margin. RIGL currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RIGL ACTIVE Rigel Pharmaceuticals Inc.	B	74/100	—	93.3%	28.2%	+1.40%	$961.1M	Benchmark Subject
KURA Kura Oncology Inc.	E	29/100	—	—	-35.0%	-1.49%	$939.4M	/kura-vs-rigl →
AKTS Aktis Oncology Inc.	D+	56/100	—	—	—	+0.18%	$937.2M	/akts-vs-rigl →
ORIC Oric Pharmaceuticals Inc.	D-	39/100	—	—	-33.4%	-3.33%	$931.8M	/oric-vs-rigl →
CYRX CryoPort Inc.	D-	38/100	11.8x	47.1%	-11.5%	-1.88%	$926.4M	/cyrx-vs-rigl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001034842

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rigel Pharmaceuticals Inc. (RIGL) reported GAAP revenue of $294.3M (+64.1% vs. FY2024 revenue of $179.3M , and +151.8% cumulative change since FY2023) , GAAP net income of $367.0M, operating cash flow of $75.7M, and free cash flow of $75.7M (+140.4% YoY). On the balance sheet, RIGL closed FY2025 with $513.6M in total assets against $0 in total debt (Altman Z-Score: 3.64, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$294.3M	$367.0M	$75.7M	$75.7M	$513.6M	—
FY2024 (FY)	2024-12-31	$179.3M	$17.5M	$31.5M	$31.5M	$164.0M	—
FY2023 (FY)	2023-12-31	$116.9M	-$25.1M	-$5.7M	-$5.7M	—	—

3. RIGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RIGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $51.45 (+1.40% 1D, market cap $961.1M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, RIGL ranks #56 in composite RQD confidence.

How does RIGL compare to KURA and AKTS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RIGL carries a Roarable B (74/100 RQD), trailing P/E of N/A, gross margin of 93.3%, and ROIC of 28.2%. By comparison, KURA (Kura Oncology Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $939.4M) and AKTS (Aktis Oncology Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $937.2M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while RIGL leads on capital efficiency (28.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RIGL?

Per RIGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001034842), Rigel Pharmaceuticals Inc. generated $294.3M in revenue (+64.1% YoY), $367.0M in net income, and $75.7M in free cash flow against $513.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RIGL trading relative to its 50-day, 200-day, and 52-week technical levels?

RIGL last traded at $51.45 (+1.40% on volume of 159,584 shares), positioning the stock +7.88% above its 50-day simple moving average ($47.69) and +38.49% above its 200-day simple moving average ($37.15). Across its 52-week range of $24.95 to $52.61, RIGL sits at the 95.8% percentile with a 14-day RSI of 64.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.8% ($47.44 to $55.46).

RIGL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell RIGL stock right now?

Rigel Pharmaceuticals Inc. (RIGL) currently earns a Roarable Rating of B (Buy — BUY) with 74/100 RQD Confidence. High-quality cash engine (93% profit margin, 28% return on capital) with steady institutional support.

What is RIGL's 12-month price target and RQD AI Jury consensus?

RIGL's 12-month base price target is $55.15 (range $42.19 to $65.08), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: RIGL RQD Cockpit RIGL 12M Forecast RIGL Earnings & Move RIGL Dividends & DRIP RIGL Insiders & 13F RIGL Whale Options RIGL Profit Sankey RIGL News & Why